About HDL Therapeutics
HDL Therapeutics is a company based in Short Hills (United States) founded in 2010. HDL Therapeutics has raised $17.79 million across 6 funding rounds. HDL Therapeutics offers products and services including PDS-2 System. HDL Therapeutics operates in a competitive market with competitors including Silk Road Medical, Supira Medical, Lifetech Scientific Corporation, Shanghai Baixin'an Biotechnology and AVS Pulse, among others.
- Headquarter Short Hills, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Hdl Therapeutics, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$17.79 M (USD)
in 6 rounds
-
Latest Funding Round
$1.27 M (USD), Series B
Jul 07, 2023
-
Investors
Not available
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of HDL Therapeutics
HDL Therapeutics offers a comprehensive portfolio of products and services, including PDS-2 System.
FDA-approved therapy to regress plaques using HDL cholesterol
People of HDL Therapeutics
Unlock access to complete
Unlock access to complete
Funding Insights of HDL Therapeutics
HDL Therapeutics has successfully raised a total of $17.79M across 6 strategic funding rounds. The most recent funding activity was a Series B round of $1.27 million completed in July 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investments & Acquisitions by HDL Therapeutics
Investment portfolio details for HDL Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - HDL Therapeutics
Detailed financials for HDL Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Hdl Therapeutics Comparisons
Peer comparison for HDL Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of HDL Therapeutics
HDL Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Silk Road Medical, Supira Medical, Lifetech Scientific Corporation, Shanghai Baixin'an Biotechnology and AVS Pulse, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Provider of neuroprotection devices for carotid artery disease
|
|
| Locked | Locked | Locked |
Developer of ventricular assist devices for coronary intervention and cardiogenic shock
|
|
| Locked | Locked | Locked |
Interventional devices for cardiovascular and vascular diseases are developed.
|
|
| Locked | Locked | Locked |
A bioabsorbable coronary rapamycin-eluting stent system is developed using PLLA.
|
|
| Locked | Locked | Locked |
Pulsatile intravascular lithotripsy is developed for calcified arterial disease treatment.
|
Detailed competitors of HDL Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Hdl Therapeutics
Complete news archive for HDL Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about HDL Therapeutics
HDL Therapeutics was founded in 2010 and raised its 1st funding round 3 years after it was founded.
HDL Therapeutics is headquartered in Short Hills, United States. It is registered at Short Hills, New Jersey, United States.
HDL Therapeutics is a funded company, having raised a total of $17.79M across 6 funding rounds to date.
HDL Therapeutics was founded in 2010 and is based in Short Hills, United States. Focus is placed on the biotechnology sector, where the PDS-2 System is developed as a therapeutic device. Patient plasma is utilized to generate natural pre-β HDL, by which plaques are reduced in coronary arteries. Cardiovascular disorder risks are thereby lowered through these operations.
HDL Therapeutics's top competitors include Silk Road Medical, Lifetech Scientific Corporation and InterShunt Technologies.
HDL Therapeutics offers PDS-2 System.